Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
- PMID: 16329139
- DOI: 10.1002/cncr.21579
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Abstract
Background: The objective of this study was to assess the antitumor activity and toxicity profile of weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Methods: Patients with recurrent, metastatic, incurable squamous cell carcinoma of the head and neck were enrolled. Weekly docetaxel (30 mg/m2) was administered for 4 weeks every 5 weeks for a maximum of 6 cycles.
Results: The activity and toxicity of docetaxel were assessed in all 38 patients who were entered on the study. No Grade 3-4 toxicities were recorded. No treatment delays were required because of toxicity or dose reductions. Responses were observed in 42% of patients (95% confidence interval, 26-58%). The median duration of response was 8.39 months, the estimated median overall survival was 11.3 months, and the 1-year survival rate was 39%.
Conclusions: The results of this study suggested that weekly docetaxel was an active agent for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Copyright 2005 American Cancer Society.
Similar articles
-
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.Am J Clin Oncol. 2011 Oct;34(5):472-7. doi: 10.1097/COC.0b013e3181ec5f16. Am J Clin Oncol. 2011. PMID: 20938321 Clinical Trial.
-
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.Eur J Cancer. 2004 Sep;40(14):2071-6. doi: 10.1016/j.ejca.2004.05.019. Eur J Cancer. 2004. PMID: 15341981 Clinical Trial.
-
Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.Laryngoscope. 2006 Apr;116(4):613-8. doi: 10.1097/01.mlg.0000208366.34683.58. Laryngoscope. 2006. PMID: 16585868 Clinical Trial.
-
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.Br J Cancer. 1999 Oct;81(3):457-62. doi: 10.1038/sj.bjc.6690715. Br J Cancer. 1999. PMID: 10507770 Free PMC article. Review.
-
The role of docetaxel in the management of squamous cell cancer of the head and neck.Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):83-7. Oncology (Williston Park). 2002. PMID: 12108901 Review.
Cited by
-
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.Cancer. 2009 Oct 1;115(19):4504-13. doi: 10.1002/cncr.24528. Cancer. 2009. PMID: 19634157 Free PMC article. Clinical Trial.
-
Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy.Eur Arch Otorhinolaryngol. 2014 Feb;271(2):373-8. doi: 10.1007/s00405-013-2537-6. Epub 2013 May 4. Eur Arch Otorhinolaryngol. 2014. PMID: 23644939
-
Docetaxel in the treatment of squamous cell carcinoma of the head and neck.Ther Clin Risk Manag. 2008 Oct;4(5):865-86. doi: 10.2147/tcrm.s3133. Ther Clin Risk Manag. 2008. PMID: 19209269 Free PMC article.
-
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.Clin Cancer Res. 2008 Jun 1;14(11):3536-44. doi: 10.1158/1078-0432.CCR-07-4025. Clin Cancer Res. 2008. PMID: 18519787 Free PMC article.
-
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.BMC Cancer. 2014 Jul 10;14:504. doi: 10.1186/1471-2407-14-504. BMC Cancer. 2014. PMID: 25011678 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
